• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BIO-TECHNE ANNOUNCES NEW DISTRIBUTION AGREEMENT WITH LEADER LIFE SCIENCES

    11/20/24 7:00:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $TECH alert in real time by email

    MINNEAPOLIS, Nov. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities today announced a partnership with Leader Life Sciences. Under the agreement, Leader Life Sciences becomes a distributor of Bio-Techne's portfolio across the Gulf Cooperation Council (GCC) countries, which include Bahrain, Oman, Qatar, Saudi Arabia, and United Arab Emirates.

    Founded in 2020, Leader Life Sciences is a scientific solutions provider dedicated to empowering the research and diagnostic community in the Middle East and North Africa (MENA) region. Serving as a catalyst for innovation, they collaborate with private and public research centers, educational institutions, and healthcare facilities to bring scientific visions to life. Their expertise spans a wide range of domains, including lab automation, digital pathology, turnkey laboratory projects and diagnostics, and beyond. Under this agreement, Leader Life Sciences will distribute Bio-Techne's extensive portfolio of innovative products, including antibodies, proteins, immunoassay kits, enzymes, small molecules, proteomic analysis instruments, and spatial biology tools to biopharma companies, laboratories, hospitals, and universities in the GCC region.

    "We are excited to partner with Leader Life Sciences to expand the reach of our products and services throughout the GCC countries," said Dr. Peter Schüßler, Vice President and General Manager of Bio-Techne's EMEA region. "Leader Life Sciences' extensive distribution network and industry expertise paired with Bio-Techne's innovative portfolio is the ideal combination to catalyze advances in science and medicine in the region."

    "We are thrilled to partner with Bio-Techne, a global leader in innovative life sciences solutions. This collaboration marks a pivotal step in our mission to empower researchers, scientists, and diagnosticians in the MENA region. Together, we are committed to providing cutting-edge technologies that accelerate discovery and enhance advancements in diagnostics, reinforcing our dedication to driving progress of the scientific community of the region," said Nirmal Kumar, Managing Director at Leader Life Sciences.

    For more information about Bio-Techne and its range of products and services, visit our Website.

    About Bio-Techne:

    Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has over 3,100 employees worldwide. For more information on Bio-Techne and its brands, please visit https://www.bio-techne.com or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube.

    Bio-Techne Contact:

    David Clair, Vice President, Investor Relations & Corporate Development

    [email protected]

    612-656-4416

    Leader Life Sciences Contact:

    [email protected]

    [email protected]

    BT Logo (PRNewsfoto/Bio-Techne Corporation)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-new-distribution-agreement-with-leader-life-sciences-302311108.html

    SOURCE Bio-Techne Corporation

    Get the next $TECH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What is the main focus of the partnership announced by Bio-Techne Corporation?

      Bio-Techne Corporation has partnered with Leader Life Sciences to distribute its products across the Gulf Cooperation Council (GCC) countries, including Bahrain, Oman, Qatar, Saudi Arabia, and the United Arab Emirates.

    • What types of products will Leader Life Sciences distribute under the new agreement?

      Leader Life Sciences will distribute a variety of Bio-Techne's innovative products, such as antibodies, proteins, immunoassay kits, enzymes, and proteomic analysis instruments.

    • What is the mission of Leader Life Sciences as described in the announcement?

      Leader Life Sciences aims to empower the research and diagnostic community in the MENA region by providing cutting-edge technologies that improve diagnostics and accelerate scientific discovery.

    • How much did Bio-Techne Corporation report in net sales for fiscal 2024?

      Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024.

    • What are the anticipated impacts of the partnership on science and medicine in the GCC region?

      The collaboration between Bio-Techne and Leader Life Sciences is expected to enhance advancements in science and medicine in the GCC region, leveraging both companies' strengths.

    Recent Analyst Ratings for
    $TECH

    DatePrice TargetRatingAnalyst
    9/3/2025$73.00Sector Perform → Outperform
    RBC Capital Mkts
    8/21/2025$70.00Neutral → Buy
    Citigroup
    7/22/2025$65.00Overweight
    Stephens
    7/9/2025$65.00Buy
    TD Cowen
    5/30/2025$59.00Overweight
    Wells Fargo
    4/9/2025Overweight → Sector Weight
    KeyBanc Capital Markets
    3/18/2025$75.00Outperform
    Evercore ISI
    2/19/2025$88.00 → $68.00Outperform → Neutral
    Robert W. Baird
    More analyst ratings

    $TECH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bio-Techne Announces Changes to its Leadership Team

    Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions Division, has been appointed President, Diagnostics and Spatial Biology Segment, effective March 1, 2026MINNEAPOLIS, Feb. 11, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth transition.

    2/11/26 9:00:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bio-Techne Declares Dividend

    MINNEAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2025. The quarterly dividend will be payable February 27, 2026, to all common shareholders of record on February 16, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of s

    2/4/26 6:30:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bio-Techne Releases Second Quarter Fiscal 2026 Results

    MINNEAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ending December 31, 2025. Second Quarter FY2026 Highlights Second quarter revenue was $295.9 million with reported and organic growth flat to prior year.GAAP earnings per share (EPS) was $0.24 versus $0.22 one year ago. Delivered adjusted EPS of $0.46 compared to $0.42 one year ago.Ongoing productivity and cost containment initiatives led to 31.1% adjusted operating margin, an increase of 100 basis points compared to the prior year period.Strong commercial execution and improving end-markets drove growth in the China/APAC region for the third consecutive

    2/4/26 6:30:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Herr Amy E. covered exercise/tax liability with 16 shares and converted options into 38 shares (SEC Form 4)

    4 - BIO-TECHNE Corp (0000842023) (Issuer)

    2/5/26 6:30:33 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President - Diag & Spatial Bio Mcmanus Matthew converted options into 4,621 shares and covered exercise/tax liability with 1,665 shares, increasing direct ownership by 62% to 7,691 units (SEC Form 4)

    4 - BIO-TECHNE Corp (0000842023) (Issuer)

    2/3/26 5:04:06 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Executive Officer Kelderman Kim covered exercise/tax liability with 2,303 shares, decreasing direct ownership by 5% to 48,665 units (SEC Form 4)

    4 - BIO-TECHNE Corp (0000842023) (Issuer)

    11/5/25 4:46:58 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECH
    SEC Filings

    View All

    Bio-Techne Corp filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - BIO-TECHNE Corp (0000842023) (Filer)

    2/11/26 4:30:18 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Bio-Techne Corp

    10-Q - BIO-TECHNE Corp (0000842023) (Filer)

    2/4/26 4:31:13 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bio-Techne Corp filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - BIO-TECHNE Corp (0000842023) (Filer)

    2/4/26 6:30:11 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bio-Techne upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Bio-Techne from Sector Perform to Outperform and set a new price target of $73.00

    9/3/25 8:14:45 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bio-Techne upgraded by Citigroup with a new price target

    Citigroup upgraded Bio-Techne from Neutral to Buy and set a new price target of $70.00

    8/21/25 8:10:31 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Stephens resumed coverage on Bio-Techne with a new price target

    Stephens resumed coverage of Bio-Techne with a rating of Overweight and set a new price target of $65.00

    7/22/25 7:51:31 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECH
    Financials

    Live finance-specific insights

    View All

    Bio-Techne Declares Dividend

    MINNEAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2025. The quarterly dividend will be payable February 27, 2026, to all common shareholders of record on February 16, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis. Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of s

    2/4/26 6:30:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bio-Techne Releases Second Quarter Fiscal 2026 Results

    MINNEAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today reported its financial results for the second quarter ending December 31, 2025. Second Quarter FY2026 Highlights Second quarter revenue was $295.9 million with reported and organic growth flat to prior year.GAAP earnings per share (EPS) was $0.24 versus $0.22 one year ago. Delivered adjusted EPS of $0.46 compared to $0.42 one year ago.Ongoing productivity and cost containment initiatives led to 31.1% adjusted operating margin, an increase of 100 basis points compared to the prior year period.Strong commercial execution and improving end-markets drove growth in the China/APAC region for the third consecutive

    2/4/26 6:30:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bio-Techne to Host Conference Call on February 4, 2026, to Announce Second Quarter Fiscal 2026 Financial Results

    MINNEAPOLIS, Jan. 20, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that management will host a conference call and webcast on Wednesday, February 4, 2026, at 8:00 a.m. CST to review its second quarter fiscal 2026 financial results. Access to the discussion may be obtained as follows: Time: 8:00 a.m. CST Date: February 4, 2026 Dial-in:  1-800-579-2543 or 1-785-424-1789 (for international callers) Conference ID: TECHQ2 Webcast: https://investors.bio-techne.com/ir-calendar A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and r

    1/20/26 7:00:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Bio-Techne Corp

    SC 13G - BIO-TECHNE Corp (0000842023) (Subject)

    11/14/24 1:22:36 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Bio-Techne Corp (Amendment)

    SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)

    2/13/24 5:00:46 PM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Bio-Techne Corp (Amendment)

    SC 13G/A - BIO-TECHNE Corp (0000842023) (Subject)

    2/9/23 11:12:40 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $TECH
    Leadership Updates

    Live Leadership Updates

    View All

    Bio-Techne Appoints Dr. Amy E. Herr to Board of Directors

    MINNEAPOLIS, Feb. 4, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company's Board of Directors beginning on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors. Dr. Herr is a Chancellor's Professor of Bioengineering at the University of California, Berkeley. Dr. Herr also currently serves as the Vice President of the Chan Zuckerberg Biohub Network, a group of nonprofit research institutes established to create tools required to understand the mysteries of the cell to ultimately cure, prevent, and manage human disease. Since joining th

    2/4/25 7:00:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BIO-TECHNE APPOINTS DR. JUDITH KLIMOVSKY TO BOARD OF DIRECTORS

    MINNEAPOLIS, April 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced the appointment of Dr. Judith Klimovsky to serve as an independent director on the Company's Board of Directors, April 24, 2024. Dr. Klimovsky will serve as a member of the Science and Technology Committee. Following the appointment, the board of Bio-Techne will be temporarily comprised of eleven directors, ten of whom are independent. Dr. Klimovsky is currently the Executive Vice President and Chief Development Officer at Genmab, an international biotechnology company specialized in the creation and development of antibody therapeutics. Before joining Genmab in 2017, Dr. Klimovsky held various s

    4/30/24 7:00:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BIO-TECHNE ANNOUNCES APPOINTMENT OF MATTHEW F. McMANUS AS PRESIDENT, DIAGNOSTICS AND GENOMICS SEGMENT

    MINNEAPOLIS, Jan. 5, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced Matthew F. McManus has been appointed President, Diagnostics and Genomics Segment, effective January 8, 2024. Dr. McManus succeeds Kim Kelderman, who will become Bio-Techne's Chief Executive Officer effective February 1, 2024. Dr. McManus has over two decades of experience as a senior life sciences leader, most recently serving as Executive Vice President and Chief Operating Officer for Azenta, where he was responsible for Life Sciences Products, Services, and all commercial operations of the business. Previously, Dr. McManus was Senior Vice President and General Manager of Bio-Techne's Molecular D

    1/5/24 7:00:00 AM ET
    $TECH
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care